OncBioMune Pharmaceuticals

October 11, 2018

OncBioMune Readies for Enrollment in Phase 2 Trial of ProscaVax Vaccine

News

OncBioMune Pharmaceuticals soon will initiate a Phase 2 trial evaluating the effectiveness and safety of its lead immunotherapy, ProscaVax, for men with early-stage prostate cancer. In a recent update, the company announced that ... Read more

July 16, 2018July 16, 2018

Phase 2 Trial of Potential Prostate Cancer Vaccine, ProscaVax, Soon to Enroll Early-stage Patients

News

OncBioMune Pharmaceuticals will soon start a Phase 2 clinical trial of its investigational vaccine ProscaVax in people with early-stage prostate cancer. ProscaVax consists of a combination of the PSA protein (a ... Read more

January 17, 2018

ProscaVax Reduced Tumor Growth in 70% of Prostate Cancer Patients, Early-stage Study Shows

News

OncBioMune‘s investigational cancer vaccine ProscaVax reduced tumor growth in 70% of prostate cancer patients included in a Phase 1a study. The immunotherapy candidate consists of a combination of the PSA protein ... Read more

November 14, 2017November 14, 2017

ProscaVax Vaccine Stopped Prostate Cancer Progression in 80% of Patients, Phase 1 Trial Shows

News

Six injections of OncBioMune Pharmaceuticals‘ prostate cancer vaccine ProscaVax stopped the progression of the disease in 80 percent of patients in a Phase 1 clinical trial, the company announced. The results applied to ... Read more

October 4, 2017

ProscaVax Vaccine Safe for Recurrent Prostate Cancer Patients, Phase 1a/1b Trial Shows

News

ProscaVax, a cancer vaccine developed by OncBioMune Pharmaceuticals, is safe for the treatment of recurrent prostate cancer patients, data from a Phase 1a/1b trial shows. The vaccine did not cause ... Read more